Factors Associated with Ocular Disorders in Children with Systemic Lupus Erythematosus (SLE)
DOI:
https://doi.org/10.37287/ijghr.v8i4.1198Keywords:
ocular disorders, pediatric, risk factors, systemic lupus erythematosus, treatment durationAbstract
Systemic lupus erythematosus (SLE) is a chronic inflammatory disease involving multiple organs and causing systemic damage, characterized by the formation of autoantibodies and immune complexes. Ocular involvement is estimated to occur in approximately one-third of individuals with SLE and may affect various ocular structures. Ocular manifestations associated with SLE are highly variable and may lead to delayed diagnosis, potentially resulting in poor outcomes and vision-threatening complications. To analyze risk factors associated with ocular disorders in children with systemic lupus erythematosus (SLE). This was an analytic cross-sectional study conducted at the Allergy-Immunology outpatient clinic and pediatric inpatient ward of Adam Malik General Hospital starting in April 2025. The sampling technique used was consecutive sampling. A total of 41 patients with SLE were analyzed. The duration of treatment was found to be a risk factor associated with ocular disorders in children with SLE (p=0.005). The prevalence of ocular disorders among children with SLE was 29.3%. The most common ocular disorder observed in children with SLE undergoing treatment was ocular hypertension, found in 9 patients (22%). Based on ordinal regression analysis, each additional year of treatment duration increased the likelihood of worsening therapeutic outcomes by 1.76 times (p<0.05). Treatment duration is a significant risk factor for ocular disorders in children with systemic lupus erythematosus, with ocular hypertension being the most common type of ocular disorder. Longer treatment duration increases the likelihood of worsening therapeutic outcomes.
References
Hsu CS, Hsu CW, Lu MC, Koo M. Risks of ophthalmic disorders in patients with systemic lupus erythematosus: a secondary cohort analysis of population-based claims data. BMC Ophthalmol. 2020;20(1):96.
Musa M, Chukwuyem E, Ojo OM, Topah EK, Spadea L, Salati C, et al. Unveiling ocular manifestations in systemic lupus erythematosus. J Clin Med. 2024;13(4):1047.
Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151–1159.
Infantino M, Manfredi M, Bizzaro N; Study Group on Autoimmune Diseases of the Italian Society of Clinical Pathology and Laboratory Medicine. European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologist's point of view. Ann Rheum Dis. 2021;80(12):e188.
Luboń, W., Luboń, M., Kotyla, P. and Mrukwa-Kominek, E. (2022) ‘Understanding ocular findings and manifestations of systemic lupus erythematosus: update review of the literature’, International Journal of Molecular Sciences, 23(20), p. 12264.
Tang, S., Lim, S.C. and Arkachaisri, T. (2021) ‘Childhood-onset systemic lupus erythematosus: southeast asian perspectives’, Journal of Clinical Medicine, 10, p. 559.
Dammacco R. Systemic lupus erythematosus and ocular involvement: an overview. Clin Exp Med. 2018;18(2):135–149.
Charras A, Smith E, Hedrich CM. Systemic Lupus Erythematosus in Children and Young People. Curr Rheumatol Rep. 2021;23(3):20.
Smith EMD, Lythgoe H, Midgley A, Beresford MW, Watson L, Marks SD, et al. Juvenile-onset systemic lupus erythematosus: update on clinical presentation, pathophysiology and treatment options. Clin Immunol. 2019;209:108274
Gawdat G, El-Fayoumi D, Marzouk H, Abouelkheir H, Abdelrahman A, El-Sayed Y, et al. Ocular manifestations in children with juvenile-onset systemic lupus erythematosus. Semin Ophthalmol. 2017;32(6):679–685.
Blum-Hareuveni T, Seguin-Greenstein S, Kramer M, et al. Risk Factors for the Development of Cataract in Children with Uveitis. 2016; 1–10.
Gao N, Li MT, Li YH, et al. Retinal vasculopathy in patients with systemic lupus erythematosus. Lupus. 2017; 26: 1182–1189.
Meng L, Wang Y, Yang Z, Zhang Y, Liu J, Chen H, et al. Ocular fundus changes and association with systemic conditions in systemic lupus erythematosus. Front Immunol. 2024;15: 1–12.
Alderaan K, Sekicki V, Magder LS, et al. Risk factors for cataracts in systemic lupus erythematosus (SLE). Rheumatol Int 2015; 35: 701–708.
Miettunen PM, Ortiz-Alvarez O, Petty RE, et al. Gender and ethnic origin have no effect on longterm outcome of childhood-onset systemic lupus erythematosus. Journal of Rheumatology 2004; 31: 1650–1654.
Shamim R, Farman S, Batool S, Khan SEA, Raja MKH. Association of systemic lupus erythematosus disease activity index score with clinical and laboratory parameters in pediatric onset systemic lupus erythematosus. Pak J Med Sci. 2020 Mar-Apr;36(3):467-472
Rasha E. Gheith, Iman I. El-Gazzar, Hussein S. El Fishawy, Abeer M. Nour El-Din, Dina M.R. Bahgat, Tamer A. Gheita, Juvenile and juvenile-onset systemic lupus erythematosus patients: Clinical characteristics, disease activity and damage, Egyptian Pediatric Association Gazette. 2017. 65(2). p49-53.
Moschetti L, Piantoni S, Vizzardi E, Sciatti E, Riccardi L, Franceschini F, et al. Endothelial dysfunction in systemic lupus erythematosus and systemic sclerosis: a common trigger for different microvascular diseases. Front Med (Lausanne). 2022;9:1–14.
Yan H, Tan X, Yu J, et al. The occurrence timeline of steroid-induced ocular hypertension and cataract in children with systemic autoimmune diseases. Int Ophthalmol 2022; 42: 2175–2184.
Popa R, Lautaru LA, Lucretiu R, et al. Therapy Side Effects in Systemic Lupus Erythematosus. Curr Health Sci J 2018; 44: 316–321
Li H, Chen C, Yang H, et al. Efficacy and safety of belimumab combined with the standard regimen in treating children with lupus nephritis. Eur J Pediatr 2024; 183: 3987–3995.
Pan L, Liu J, Liu C, et al. Childhood-onset systemic lupus erythematosus: characteristics and the prospect of glucocorticoid pulse therapy. Front Immunol 2023; 14: 1–11.
Sit JKK, Chan WKY. Risk factors for damage in childhood-onset systemic lupus erythematosus in Asians: a case control study. Pediatric Rheumatology 2018; 16: 1–11.
Puengpipattrakul T, Lerkvaleekul B, Pirojsakul K, et al. Risk factors associated with multiple organ damage in childhood-onset systemic lupus erythematosus. 2023; 1–9.
Li H, Chen C, Yang H, et al. Efficacy and safety of belimumab combined with the standard regimen in treating children with lupus nephritis. Eur J Pediatr 2024; 183: 3987–3995.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Indonesian Journal of Global Health Research
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
